-
EP4204459
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4204459
| EP4204459 - TARGETED PROTEIN DEGRADATION IN THERAPEUTIC CELLS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 02.06.2023 Database last updated on 24.08.2024 | |
| Former | The international publication has been made Status updated on 05.03.2022 | Most recent event Tooltip | 28.02.2024 | New entry: Additional fee for renewal fee: payment of fee | 28.02.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states The Regents of the University of California 1111 Franklin Street, 12th Floor Oakland, CA 94607 / US | [2023/27] | Inventor(s) | 01 /
NG, Andrew H. San Francisco, California 94143 / US | 02 /
KIM, Matthew San Francisco, California 94143 / US | [2023/27] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2023/27] | Application number, filing date | 21862594.5 | 24.08.2021 | [2023/27] | WO2021US47391 | Priority number, date | US202063070166P | 25.08.2020 Original published format: US 202063070166 P | [2023/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022046802 | Date: | 03.03.2022 | Language: | EN | [2022/09] | Type: | A1 Application with search report | No.: | EP4204459 | Date: | 05.07.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.03.2022 takes the place of the publication of the European patent application. | [2023/27] | Search report(s) | International search report - published on: | US | 03.03.2022 | Classification | IPC: | C07K16/30, C07K14/705, C12N9/50, C12N5/0783 | [2023/27] | CPC: |
C12N5/0636 (EP,US);
A61K2239/23 (EP,US);
A61K2239/48 (EP,US);
A61K38/1709 (US);
A61K39/4611 (EP,US);
A61K39/4631 (EP,US);
A61K39/46433 (US);
A61K39/464406 (EP,US);
A61K39/464412 (EP,US);
C07K16/084 (EP);
C07K16/30 (EP);
C07K2317/622 (EP);
C07K2319/03 (EP);
C07K2319/33 (EP);
C07K2319/95 (EP);
C12N2510/00 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/27] | Title | German: | GEZIELTER PROTEINABBAU IN THERAPEUTISCHEN ZELLEN | [2023/27] | English: | TARGETED PROTEIN DEGRADATION IN THERAPEUTIC CELLS | [2023/27] | French: | DÉGRADATION DE PROTÉINE CIBLÉE DANS DES CELLULES THÉRAPEUTIQUES | [2023/27] | Entry into regional phase | 24.02.2023 | National basic fee paid | 24.02.2023 | Search fee paid | 24.02.2023 | Designation fee(s) paid | 24.02.2023 | Examination fee paid | Examination procedure | 24.02.2023 | Examination requested [2023/27] | 12.10.2023 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 28.02.2024 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.08.2023 | 03 M06 Fee paid on 28.02.2024 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [X]US2016272718 (WANG BENJAMIN [US], et al); | [A]WO2020010239 (UNIV LELAND STANFORD JUNIOR [US]) |